PSM Great Debate: Prophylactic CRS/HIPEC in High-risk T4 Colorectal Cancer

Moderator(s)

• 

  Fabian Johnston, MD, MHS

  Associate Professor of Surgery
  Division of Gastrointestinal Surgical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States
  Baltimore, Maryland, United States

  Disclosure(s): No financial relationships to disclose

A significant proportion of colorectal cancer patients with T4 disease will go on to develop peritoneal metastases, often without involvement in other area. Clinical and pharmacokinetic data hypothesize that the effectiveness of intraperitoneal chemotherapy is greatest when the disease is microscopic but there is insufficient robust evidence to ascertain whether the addition of HIPEC for high-risk colorectal cancers provides better control of local recurrence over systemic therapy.

Presentations:

• 10:30am – 10:45am ET

  Pro: All Patients with High-risk T4 Colorectal Cancer should undergo Prophylactic CRS/HIPEC
  

  Debater: Laura A. Lambert, MD – Division of Surgical Oncology, University of Utah, Salt Lake City, UT, United States
• 10:45am – 11:00am ET

  Con: Prophylactic CRS/HIPEC is not indicated in Patients with High0risk T4 Colorectal Cancer
  

  Debater - Con: Konstantinos I. Votanopoulos, MD, PhD, FACS – Wake Forest Baptist Medical Center
• 11:00am – 11:15am ET

  Rebuttals - Q&A -Discussion